Constipation, flatulence, burping, and more: Is something wrong?
Yale doctors share some of the GI issues they frequently treat, suggest steps you can take at home — and explain when you should seek advice from a physician. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 15, 2021 Category: Universities & Medical Training Source Type: news
What causes constipation? The two drinks you should AVOID
CONSTIPATION is a common problem where you can't manage to go to the toilet enough. But what causes it and are there certain foods and drinks to avoid? (Source: Daily Express - Health)
Source: Daily Express - Health - July 15, 2021 Category: Consumer Health News Source Type: news
A Closer Look at the Colon Condition That Hospitalized the Pope
Francis suffered a disorder that is relatively common and treatable, and doctors expect him to make a full recovery. (Source: NYT Health)
Source: NYT Health - July 5, 2021 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Colon Digestive Tract Surgery and Surgeons Antibiotics Constipation Fiber (Dietary) Diverticulosis Age, Chronological Roman Catholic Church Gemelli Francis Source Type: news
How to deal with common digestive problems
Stomach woes become more common with age. Lifestyle changes can make a big difference with heartburn, bloating, constipation, gas and lactose intolerance. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - June 28, 2021 Category: Consumer Health News Authors: Sally Wadyka Source Type: news
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and w...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Is Constipation Normal in the First Trimester
Is It Normal to Be Constipated in the First Trimester? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 27, 2021 Category: General Medicine Source Type: news
Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO® in combi...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that ...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Healing Words: The Opioid-Induced Constipation Crisis
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - May 1, 2021 Category: Emergency Medicine Tags: Healing Words Source Type: news
Three More Things We Do for No Reason in Pediatrics Three More Things We Do for No Reason in Pediatrics
The Cribsiders share their favorite easy-to-implement pearls on CAP, cellulitis, and constipation in kids.The Cribsiders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 30, 2021 Category: Consumer Health News Tags: Pediatrics Commentary Source Type: news
Get Moving on Constipation
Dear Dr. Jeff: Recently our facility had a patient who complained of abdominal pain and vomiting. She was sent to the emergency department where she received a Fleet enema and was returned with a diagnosis of “fecal impaction.” The family complained to surveyors who cited us for a Level G deficiency and imposed a $5,000 fine. The facility leadership has focused on the decision to transfer the resident to the hospital as the problem, but it seems to me that more needs to be fixed. Any suggestions? (Source: Caring for the Ages)
Source: Caring for the Ages - April 28, 2021 Category: Health Management Authors: Jeffrey Nichols Tags: Dear Dr. Jeff Source Type: news
Dramatic Rise in Use of Drugs for Opioid-Induced Constipation Dramatic Rise in Use of Drugs for Opioid-Induced Constipation
Use of these drugs soared during a period of 4 years, propelled by a Super Bowl advertisement, prompting calls for defining appropriate use of these agents.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 27, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Diabetes type 2 symptoms: Constipation may indicate nerve damage
DIABETES may continue to disrupt your internal processes, with symptoms so slight, you don't realise the significant damage being done inside. Struggling to release bowel movements might be more sinister than once thought. (Source: Daily Express - Health)
Source: Daily Express - Health - April 18, 2021 Category: Consumer Health News Source Type: news
Constipation treatment Vibrant raises $7.5 million led by Unorthodox Ventures
Sequoia Capital invests for fourth time as treatment continues third round of FDA trials
YOKNEAM ILLIT, Israel, March 26, 2021 -- (Healthcare Sales & Marketing Network) -- Vibrant, a leading developer of gastrointestinal treatments, today announced the... Devices, Gastroenterology, Venture Capital Vibrant Ltd, vibrating capsule (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 26, 2021 Category: Pharmaceuticals Source Type: news
